Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

In a moment of both triumph and uncertainty, South Africa's scientific community has unveiled encouraging results from a landmark HIV cure trial conducted in Durban, KwaZulu-Natal. The University of ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against ...

Nearly 85% of the 1.7 million adolescents with HIV live in sub-Saharan Africa, along with half of the nearly 40 million ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.